Nanoscope Therapeutics' MCO-010 gene therapy for retinitis pigmentosa shows positive Phase 2b trial results, demonstrating improved visual acuity and no serious adverse events.
Nanoscope Therapeutics reports positive Phase 2b trial results for MCO-010, a mutation-agnostic gene therapy for retinitis pigmentosa. The RESTORE trial demonstrated significant improvement in best-corrected visual acuity in high-dose and low-dose treatment groups, compared to sham control. No serious adverse events were reported, and the company plans to submit a BLA to the FDA in 2024.
March 26, 2024
5 Articles